<SEC-DOCUMENT>0001437749-24-024342.txt : 20240801
<SEC-HEADER>0001437749-24-024342.hdr.sgml : 20240801
<ACCEPTANCE-DATETIME>20240801172446
ACCESSION NUMBER:		0001437749-24-024342
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20240801
DATE AS OF CHANGE:		20240801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279343
		FILM NUMBER:		241168000

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>crvo20240801_424b3.htm
<DESCRIPTION>FORM 424B3
<TEXT>
<html><head>
	<title>crvo20240801_424b3.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2024 9:18:14 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Filed pursuant to Rule 424(b)(3)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No.: 333-279343</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PROSPECTUS SUPPLEMENT No. 3</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(to the Prospectus dated June 5, 2024, as supplemented by </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prospectus Supplement No. 1, dated June 14, 2024, and </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prospectus Supplement No. 2, dated July 12, 2024)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="a01.jpg" src="a01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>5,064,570 Shares of Common Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus supplement No. 3 (the &#8220;Prospectus Supplement&#8221;) amends and supplements our prospectus contained in our Registration Statement on Form S-1, effective as of June 5, 2024, as supplemented by Prospectus Supplement No. 1, dated June 14, 2024, and Prospectus Supplement No. 2, dated July 12, 2024 (as supplemented from time to time, the &#8220;Prospectus&#8221;), related to the resale by the selling stockholders identified in the Prospectus of up to an aggregate of 5,064,570 shares of our common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus the information contained in our attached Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 1, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference to the Prospectus except to the extent that the information in this Prospectus Supplement supersedes the information contained therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our Common Stock is listed on the NASDAQ Capital Market under the symbol &#8220;CRVO.&#8221; The last reported closing price of our Common Stock on the NASDAQ Capital Market on July 31, 2024, was $13.00.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Investing in our securities involves risks. See </b>&#8220;<b>Risk Factors</b>&#8221;<b> beginning on page 9 of the Prospectus and in the documents incorporated by reference in the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this Prospectus Supplement is August 1, 2024.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" docsect="1" id="546964" sectdesc="Section">&nbsp;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 8-K</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>July 29, 2024</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>001-37942</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of incorporation)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>File Number)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="3" style="vertical-align: middle; width: 67%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 67%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>20 Park Plaza, Suite 424</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Boston, Massachusetts</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>02116</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 67%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>s telephone number, including area code: (617) 744-4400</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title of each class</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>on which registered</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common Stock, $0.001 par value</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CRVO</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">NASDAQ Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Item&nbsp;8.01</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Other Events</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 29, 2024, CervoMed Inc. (the &#8220;Company&#8221;) issued a press release announcing that plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies was featured in a poster presentation at the Alzheimer's Association International Conference&#174; held in Philadelphia, Pennsylvania from July 28-August 1, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 30, 2024, the Company issued a press release announcing that Company management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, Massachusetts, on August 13, 2024. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&nbsp;9.01</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(d)</i></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Exhibits</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></p>
			</td>
			<td style="vertical-align:bottom;width:3.3%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 85.2%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:85.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_707255.htm" style="-sec-extract:exhibit;">Press Release, issued July 29, 2024</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.2</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:85.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_707256.htm" style="-sec-extract:exhibit;">Press Release, issued July 30, 2024</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:85.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="3" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="3" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date: August 1, 2024</p>
			</td>
			<td colspan="2" style="width: 5%;" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>CervoMed Inc.</b></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 33%;" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left; width: 5%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 33%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William Elder</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:</p>
			</td>
			<td style="width: 33%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">William Elder</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:&nbsp;</p>
			</td>
			<td style="width: 33%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;Chief Financial Officer &amp; General Counsel</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 252pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_707255.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_707245.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2024 9:17:03 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-hf-endpoint="start" data-hf-html="%3Cdiv%20style%3D%22width%3A%20100%25%3B%22%3E%3Cdiv%20class%3D%22hf-row%22%3E%3Cdiv%20class%3D%22hf-cell%20TOCLink%22%20style%3D%22text-align%3A%20left%3B%20margin%3A%200pt%3B%20width%3A%2099.9%25%3B%20display%3A%20inline-block%3B%22%3E%3C%2Fdiv%3E%3C%2Fdiv%3E%3Cdiv%20class%3D%22hf-row%22%3E%3Cdiv%20class%3D%22hf-cell%22%20style%3D%22font-family%3A%20%26quot%3BTimes%20New%20Roman%26quot%3B%2C%20Times%2C%20serif%3B%20font-size%3A%2010pt%3B%20text-align%3A%20left%3B%20margin%3A%200pt%3B%20width%3A%2099.9%25%3B%20display%3A%20inline-block%3B%22%3E%3Cimg%20src%3D%22%2Fhtmleditor%2FImage%2FGetImage%3FprojId%3D107814%26amp%3BimageName%3Dlogosm.jpg%22%3E%3C%2Fdiv%3E%3C%2Fdiv%3E%3C%2Fdiv%3E" data-hf-type="header">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="logosm.jpg" src="logosm.jpg"></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB) </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase with neurodegenerative progression in DLB </i>&#8211;<i> </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>- AscenD-LB Phase 2a results demonstrated neflamapimod treatment led to significant reduction compared to placebo in plasma GFAP levels in patients with DLB and the effects of neflamapimod on plasma GFAP were associated with improvement in CDR-SB - </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston </b>&#8211;<b> July 29, 2024 </b>&#8211; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), was featured in a poster presentation at the Alzheimer's Association International Conference&#174; (AAIC), being held in Philadelphia from July 28-August 1, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;Recent developments in the field support the use of plasma GFAP to evaluate the therapeutic effects on DLB-specific disease processes, and baseline data from AscenD-LB, our Phase 2a trial, further validate the utility of this biomarker,&#8221; said John Alam, MD, Chief Executive Officer of CervoMed. &#8220;We observed a clear association between plasma GFAP and dementia severity in patients with DLB. Additionally, growing data highlights the effects of neflamapimod on GFAP&#8212;particularly its association with the positive effects on clinical outcomes &#8212;and underscore the potential to address the underlying disease process in early-stage DLB. With these critical learnings from the AscenD-LB Phase 2a trial, we believe our fully enrolled RewinD-LB Phase 2b trial is optimized for success and we remain on track to report topline data in December 2024.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The ePoster (91713) is accessible on the conference portal, and additional details are provided below. A PDF copy of the GFAP poster presentation will be available on the &#8220;<u>Presentations and Publications</u>&#8221; section of the CervoMed website.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Title: Neflamapimod treatment reduces plasma glial fibrillary acidic protein GFAP levels in patients with dementia with Lewy bodies (DLB) who do not have co-existing AD co-pathology</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Authors:&nbsp;John Alam, Marleen Koel-Simmelink, Jennifer Conway, Inge Verberk, Charlotte Teunissen; CervoMed Inc (JA and JC) and Amsterdam Medical Center (MKS, IV, CT)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Key Takeaways from the presentation:</b>&nbsp;The effects of neflamapimod on plasma GFAP were evaluated in both the overall and early-stage DLB patient population, and the treatment effects of GFAP correlated to clinical outcomes:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Baseline (BL) plasma GFAP level was highly correlated to the baseline Clinical Dementia Rating Sum of Boxes (CDR-SB) score and was significantly higher in patients with AD Co-Pathology (BL ptau181 &#8805;&nbsp;2.2 pg/mL) compared to patients without AD co-pathology (baseline ptau181 &lt; 2.2 pg/mL). Plasma GFAP was significantly elevated in both groups compared to levels in healthy controls in the literature.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: left; margin: 0pt; width: 99.9%; display: inline-block;"><img src="logosm.jpg" alt="logosm.jpg"></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In early-stage DLB patients (i.e., patients with pre-treatment plasma ptau181 below the cutoff for AD-related co-pathology), there was a mean 14.1 pg/mL increase in the placebo treatment group (N=13) vs. mean 10.6 pg/mL reduction with neflamapimod treatment (N=15; p=0.04 for the difference). In patients with advanced DLB (i.e., patients with pre-treatment plasma ptau181 above the cutoff for AD-related co-pathology), there was a mean 6.0 pg/mL decrease in the placebo group (N=14) vs. mean 14.0 pg/mL reduction with neflamapimod treatment (N=15; the difference was not significant).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the early-stage DLB patient population, in participants treated with neflamapimod there was a significant correlation (r=0.54, p=0.04) between the effects of GFAP and clinical outcomes assessed by change from baseline to week 16 in CDR-SB, with increased GFAP being associated with worsening CDR-SB, while reduction in GFAP was associated with improvement on CDR-SB. The correlation was not seen in placebo-recipients (r=0.31, p=NS).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recent developments in the field support the use of plasma GFAP as a biomarker of the underlying disease process in DLB:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Data from the Mayo Clinic (Diaz-Galvan et al, 2024) show that in patients with prodromal DLB plasma GFAP is elevated relative to healthy controls, while plasma neurofilament light chain and plasma ptau181 are not. As patients at this stage have cholinergic degeneration in the basal forebrain without significant cortical atrophy (Kantarci et al, 2022), GFAP elevation in this context appears to reflect the disease in the basal forebrain cholinergic system that is the primary driver of disease expression and progression in early-stage DLB (Okkels et al, 2024).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Data from the European Dementia with Lewy Bodies consortium (Bolsewig et al, 2024), show that in patients with DLB, plasma GFAP is associated with rate of cognitive decline, but not with CSF amyloid status, suggesting that GFAP elevation has potential to evaluate DLB-specific disease processes.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Study in Dementia with Lewy Bodies </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed&#8217;s ongoing Phase 2b study, RewinD-LB, is a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in up to 160 patients with very mild or mild dementia due to DLB. Patients completing the 16-week placebo-controlled study period will be able to continue in the study while receiving open label neflamapimod treatment for an additional 32 weeks. Patients with Alzheimer&#8217;s Disease-related co-pathology, assessed by a blood biomarker (plasma ptau181), will be excluded. The primary endpoint in the study is change in the Clinical Dementia Rating Sum of Boxes, and secondary endpoints include the Timed Up and Go test, a cognitive test battery, and the Clinician&#8217;s Global Impression of Change. The RewinD-LB study is funded by a&nbsp;$21.0 million&nbsp;grant from the&nbsp;National Institutes&nbsp;of Health&#8217;s&nbsp;National Institute on Aging, which will be disbursed over the course of the study as costs are incurred. The study includes 43 sites (32 in&nbsp;the United States, eight in the&nbsp;United Kingdom, and three in&nbsp;the Netherlands). More information on the RewinD-LB study, is available at&nbsp;<u>clinicaltrials.gov</u>. The study completed enrollment in June 2024 and topline primary efficacy results are expected in December 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: left; margin: 0pt; width: 99.9%; display: inline-block;"><img src="logosm.jpg" alt="logosm.jpg"></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of CervoMed Inc. (the Company), including, but not limited to, the therapeutic potential of neflamapimod, the anticipated timing and achievement of clinical and development milestones, including the completion and achievement of primary endpoints of the RewinD-LB Phase 2b clinical trial and the Company&#8217;s announcement of topline data therefrom, any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the RewinD-LB Trial will be replicated in later trials, and the Company&#8217;s clinical development plans. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources and the availability of additional funds on acceptable terms; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>References:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Bolsewig, K., A. van Unnik, E. R. Blujdea, et al, and European-Dementia With Lewy Bodies (2024). "Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies." <u>Neurology</u> (2024) 102): e209418</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diaz-Galvan, P., S. A. Przybelski, A. Algeciras-Schimnich, et al. "Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies." <u>Alzheimers Dement</u> (2024) 20:2485-2496</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Kantarci, K., Z. Nedelska, Q. Chen, M. et al. "Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration." <u>Brain Communications (2022)</u> 4:fcac013</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Okkels, N., M. J. Grothe, J. P. Taylor, et al. "Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes." <u>Brain</u> (2024) 147:2308-2324.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors@cervomed.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex_707256.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html><head>
	<title>ex_707246.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2024 9:16:32 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><img alt="logosm.jpg" src="logosm.jpg"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed to Participate in The Canaccord Genuity 44</b><b><sup style="vertical-align:top;line-height:120%;">th</sup></b><b> Annual Growth Conference</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston </b>&#8211;<b> July 30, 2024 </b>&#8211; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company&#8217;s Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA and participate in one-on-one investor meetings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Presentation Details </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Format: Fireside Chat</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: Tuesday, August 13, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Time: 12:30 PM ET</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Webcast Link: https://wsw.com/webcast/canaccord98/crvo/2485318</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The webcast of the fireside chat will be accessible in the Investors section of the CervoMed website https://www.cervomed.com/.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed Inc. (the &#8220;Company&#8221;) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors@cervomed.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>a01.jpg
<TEXT>
begin 644 a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BD#AB0""5ZCTI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@MJ]3.JG/@.?O9_><67QY<5R]KGYC_\ !?\ _P"4O7QE_P"ORP_]-MK7$_\
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M!YK[-HKNJ9A5GAUAG\*^_P!#FCA81JNLMV%%%%<)TGQ;_P %3_\ @B-\,_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>logosm.jpg
<TEXT>
begin 644 logosm.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M!/7:MM"RCL !V%?JM_P>!)'9^'O@!:PJL<4-SJ^Q%& JB*V  'H*E_X(#_\
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
